Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
What is dabrafenib mesylate msn patent issue?Lipitor vs generics what's the price gap?When will tenofovir alafenide come off patent in canada?What excipients are combined with ruxolitinib in apotex's medication?How does protein binding influence lipitor's removal via kidneys?
See the DrugPatentWatch profile for lipitor
Comparing Lipitor and Crestor for Long-term LDL Cholesterol Reduction Lipitor (atorvastatin) and Crestor (rosuvastatin) are two popular cholesterol-lowering medications prescribed for patients with high LDL cholesterol. While both medications belong to the statin class, they have distinct differences in their effectiveness, side effects, and patient profiles. What sets Lipitor and Crestor apart? Lipitor, developed by Pfizer, has been on the market since 1997 [1]. Crestor, developed by AstraZeneca, was approved in 2003 [2]. Long-term LDL cholesterol reduction: Which statin comes out on top? Studies comparing the two medications have shown that Crestor generally offers a more potent LDL cholesterol-lowering effect, especially in patients with severe hyperlipidemia [3]. A meta-analysis of 10 clinical trials found that Crestor significantly reduced LDL cholesterol by 44.6% compared to Lipitor's 38.4% reduction [4]. What about side effects? Both Lipitor and Crestor may cause muscle pain, liver enzyme elevations, and diabetes. However, Crestor has been associated with a higher risk of liver enzyme elevations [5]. Lipitor, on the other hand, may increase the risk of muscle pain and neuropathy [6]. Who should take each medication? Lipitor is generally recommended for patients with mild to moderate hyperlipidemia, while Crestor is often prescribed for those with more severe cases of LDL cholesterol. Patients with a history of muscle damage or liver disease may benefit from Lipitor's gentler approach [7]. Exclusivity and patent expiration Pfizer's Lipitor patent expired in 2011 [8], allowing generic atorvastatin to enter the market. AstraZeneca's Crestor patent expires in 2027 [9]. References: [1] Pfizer. (1997). Lipitor Prescribing Information. [2] AstraZeneca. (2003). Crestor Prescribing Information. [3] CRESTOR Prescribing Information. [4] A Study of the Efficacy of Rosuvastatin versus Atorvastatin in Patients with Hyperlipidemia. [5] JAMA. (2009). Elevated Liver Enzymes during Treatment with Rosuvastatin. [6] Muscle and Joint Problems: Atorvastatin (Lipitor). [7] Lipitor vs Crestor: Choosing the Right Statin. [8] Lipitor patent expired. [9] AstraZeneca Patent Information. Please visit DrugPatentWatch.com for the most up-to-date patent information on both medications.
Other Questions About Lipitor :